Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to email@example.com so that we can defer those challenges. Your health and safety are paramount to us.
Posted 13 May 2013 | By Alexander Gaffney, RAC,
The US Food and Drug Administration (FDA) may still be in the midst of figuring out how to overhaul its medical device compliance approach in regards to quality, but a new report out from device consultancy Emergo Group shows that the agency is dramatically ramping up the number of quality-related deficiencies it cites in its inspection reports.
FDA has long maintained that it has seen a troubling increase in the number of quality-related deficiencies during its facility inspections, prompting it to rethink how it approaches regulation in general.
Its recently proposed approach, which it has dubbed the "Case for Quality," is built on the premise that an increased emphasis on building quality practices in industry will allow for FDA to focus less on compliance activities. For example, companies utilizing root cause analysis and designing quality into a product are unlikely to experience recurring compliance issues, whereas a company that fixes compliance issues on a piecemeal basis is likely to experience regular problems and recurring product failures.
But if quality is the future that allows for a decreased emphasis on compliance measures, that doesn't mean FDA isn't still laser-focused on those issues.
In a new analysis report issued by Emergo, the consultancy finds that quality system-related inspections have been increasing dramatically in recent years. Since 2008, when FDA conducted 1,423 inspections, the agency had increased its quality-related inspection by more than 46%. That increase was as high as 49% in 2011, when the agency conducted 2,121 inspections, but fell slightly in 2012 to 2,087.
And more inspections have correlated closely with increased warning letters sent to manufacturers. Emergo found an increase of Warning Letters from 98 in 2008 to 164 in 2012-an increase of 67% in just four years. The four consecutive increases (2009-2012) contrast sharply with the 2004-2007 period, when the issuance of warning letters fell each year, from 113 in 2004 to just 74 in 2007.
FDA's findings of deficiencies in 2012 fall into four areas, of which two are especially prominent: Corrective and preventive action (CAPA) and Production and Process Controls (P&PC), both of which accounted for 30% of all cited deficiencies. The remaining 40% of citations were for design problems (DES) (15%), management issues (14%) and "other" problems (11%). FDA's observations during 2012 totaled 4,243, according to Emergo's analysis.
So what should medical device manufacturers take away from the data? A few things, wrote Emergo's Stewart Eisenhart.
"Medical device firms should expect the trend of stepped-up FDA inspections to continue through the Obama administration's second term. However, the data also provides a clear indication of which QSR quality system components most commonly draw scrutiny from inspectors."
"Medical device manufacturers active in the US market now know to pay particular attention to their CAPA and P&PC procedures to ensure compliance with 21 CFR Part 820," he concluded.
Tags: 483, warning letter